FDA Plays

[jrbritt]

Some basic CORT highlights

They have NDA for "Corlux" - for cushing's syndrome in the first qtr. '11
~59% held by insiders
~20% held by institutions - these two factors are very high on my priority list - i like to see management with a vested interest

Target price by most analyst of $6.50 - $7.4ish

possibly on pace for FDA prioity review in 4th qtr 2011

on Jan 11th they announced positive results on key secondary endpoint in a phase 3 study of Corlux - info on that can be read here http://www.corcept.com/news_events/pr_1294733855

on December 22nd they announced that primary endpoint was achieved for both groups in phase 3 study - info on that can be read here http://www.corcept.com/news_events/pr_1292984884

Estimated 20,000 people with Cushings in the U.S. Analysis have thrown around some numbers of $225M in sales for their target prices

There has been some speculation that they may market this drug on their own since it is somewhat specialized smaller market for a rare disease

This is all very preliminary research on my part - focused on DEPO for the next few days - but I like what I've found so far.